Drug intelligence / Profile preview

IFX-401

Development stage: Preclinical
Lead developer: Infinimmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IFX-401 is a monoclonal antibody developed by Infinimmune that targets interleukin-17F (IL-17F). It is currently in preclinical development for the treatment of ulcerative colitis (UC). IL-17F is a member of the IL-17 cytokine family and plays a significant role in driving inflammation in the gut mucosa. By selectively neutralizing IL-17F, IFX-401 is designed to mitigate the inflammatory response associated with UC while potentially offering a differentiated safety or efficacy profile compared to broader IL-17 inhibitors.

Targets

IL-17F (Interleukin-17F)

Beyond the preview

Go deeper on IFX-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFX-401.

Explore the full profile